Shanghai Uni CAR-T Cell Therapy Bio-Medicine Technology

Shanghai Uni CAR-T Cell Therapy Bio-Medicine Technology (UniCAR-T) is a clinical-stage biopharmaceutical company specializing in the development of innovative chimeric antigen receptor (CAR) T-cell therapies. The company focuses on treating hematological malignancies and solid tumors using its proprietary technology platforms, including dual-target CAR-T and universal CAR-T (UCAR-T) solutions. UniCAR-T has several programs in clinical trials targeting antigens such as CD19, CD22, and BCMA, with a particular emphasis on overcoming resistance and relapse in traditional therapies. Their research aims to improve the efficacy and safety of cell therapies while reducing manufacturing costs and increasing patient accessibility through advanced genetic engineering.